SCHEMBL10189557

SCHEMBL10189557

COc1ccc(-c2cnnn2-c2cc(C)c(C)c(OC)c2)cn1

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
PDGFRB P09619 1/20 0.40
PDGFRA P16234 1/20 0.40
CYP2A6 P11509 1/20 0.39
PTGS1 P23219 1/20 0.38
PTGS2 P35354 1/20 0.38
LMNA P02545 2/20 0.37
KDR P35968 1/20 0.37
OXTR P30559 1/20 0.36
MEN1 O00255 1/20 0.36
TP53 P04637 1/20 0.36
MAPT P10636 1/20 0.36
HPGD P15428 1/20 0.36
KMT2A Q03164 1/20 0.36
ERN1 O75460 1/20 0.36
FYN P06241 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL411500 0.86 SMN1; SMN2 (0.50) ALDH1A1SMN1; SMN2PDGFRBPDGFRAPTGS1
SCHEMBL10189553 0.84 PTGS1 (0.54) ALDH1A1SMN1; SMN2PTGS1PTGS2LMNA
SCHEMBL10189515 0.84 ALDH1A1 (0.63) ALDH1A1SMN1; SMN2PTGS1PTGS2LMNA
SCHEMBL10189570 0.83 ALDH1A1 (0.46) ALDH1A1SMN1; SMN2PTGS1PTGS2LMNA
SCHEMBL10189518 0.83 PTGS1 (0.53) ALDH1A1SMN1; SMN2PTGS1PTGS2LMNA
SCHEMBL10189512 0.83 ALDH1A1 (0.49) ALDH1A1SMN1; SMN2PTGS1PTGS2LMNA
SCHEMBL10189600 0.83 ALDH1A1 (0.49) ALDH1A1SMN1; SMN2PTGS1PTGS2LMNA
SCHEMBL10189548 0.82 ALDH1A1 (0.48) ALDH1A1SMN1; SMN2PTGS1PTGS2LMNA
SCHEMBL10189522 0.82 FLT3 (0.54) ALDH1A1SMN1; SMN2PTGS1PTGS2MAPT
SCHEMBL10189514 0.82 ALDH1A1 (0.54) ALDH1A1SMN1; SMN2PDGFRBPDGFRAPTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9175022-B2 Compounds for the treatment of proliferative disorders SYNTA PHARMACEUTICALS CORP. (US) 2015-11-03 US disclosed
US-8501790-B2 Compounds for the treatment of proliferative disorders SYNTA PHARMACEUTICALS CORP. (US) 2013-08-06 US disclosed
US-20120022118-A1 COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS SYNTA PHARMACEUTICALS CORP. 2012-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022118-A1 COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS RB1, MKI67, MAPRE1 ALDH1A1 1872/4885SMN1; SMN2 3188/4885PDGFRB 186/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.